Hürthle cell carcinoma: current perspectives.

Published online

Journal Article (Review)

Hürthle cell carcinoma (HCC) can present either as a minimally invasive or as a widely invasive tumor. HCC generally has a more aggressive clinical behavior compared with the other differentiated thyroid cancers, and it is associated with a higher rate of distant metastases. Minimally invasive HCC demonstrates much less aggressive behavior; lesions <4 cm can be treated with thyroid lobectomy alone, and without radioactive iodine (RAI). HCC has been observed to be less iodine-avid compared with other differentiated thyroid cancers; however, recent data have demonstrated improved survival with RAI use in patients with HCC >2 cm and those with nodal and distant metastases. Patients with localized iodine-resistant disease who are not candidates for a wait-and-watch approach can be treated with localized therapies. Systemic therapy is reserved for patients with progressive, widely metastatic HCC.

Full Text

Duke Authors

Cited Authors

  • Ahmadi, S; Stang, M; Jiang, XS; Sosa, JA

Published Date

  • 2016

Published In

Volume / Issue

  • 9 /

Start / End Page

  • 6873 - 6884

PubMed ID

  • 27853381

Pubmed Central ID

  • 27853381

International Standard Serial Number (ISSN)

  • 1178-6930

Digital Object Identifier (DOI)

  • 10.2147/OTT.S119980

Language

  • eng

Conference Location

  • New Zealand